Pharmacological variability of insulins degludec and glargine 300U/mL: Equivalent or not?

Affiliations

¹ University institute of clinical research, university of Montpellier, 641, avenue du Doyen-Gaston-Giraud, 34093 Montpellier cedex 5, France. Electronic address: louis.monnier@inserm.fr.
² University institute of clinical research, university of Montpellier, 641, avenue du Doyen-Gaston-Giraud, 34093 Montpellier cedex 5, France.

Editorial

L Monnier et al. Diabetes Metab. 2018 Feb.

. 2018 Feb;44(1):1-3.

doi: 10.1016/j.diabet.2017.11.001. Epub 2017 Nov 14.

¹ University institute of clinical research, university of Montpellier, 641, avenue du Doyen-Gaston-Giraud, 34093 Montpellier cedex 5, France. Electronic address: louis.monnier@inserm.fr.
² University institute of clinical research, university of Montpellier, 641, avenue du Doyen-Gaston-Giraud, 34093 Montpellier cedex 5, France.

No abstract available

Keywords: Degludec; Glargine U300; Pharmacodynamics; Pharmacokinetics.

Comment on

Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
Bailey TS, Pettus J, Roussel R, Schmider W, Maroccia M, Nassr N, Klein O, Bolli GB, Dahmen R. Bailey TS, et al. Diabetes Metab. 2018 Feb;44(1):15-21. doi: 10.1016/j.diabet.2017.10.001. Epub 2017 Nov 16. Diabetes Metab. 2018. PMID: 29153485 Clinical Trial.